Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (111-120 of 225) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Leukemia|June 23, 2025
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemiaKiyomi Mashima, Yanan Kuang, Stacey M Fernandes, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Blood Cancer Journal|February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitorsDeepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
British Journal of Haematology|January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphomaPhilippe Armand, Robert Redd, Jad Bsat, et al.
Haematologica|July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trialGeoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2018
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL RegistryAnthony Mato, Chadi Nabhan, Neil E Kay, et al.
Pageof 23

Showing results (111-120 of 225) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Blood|April 10, 2025
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Saad S Kenderian, Ian W Flinn, et al.
Leukemia|June 23, 2025
Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemiaKiyomi Mashima, Yanan Kuang, Stacey M Fernandes, et al.
Blood Advances|January 4, 2018
Early progression of disease as a predictor of survival in chronic lymphocytic leukemiaInhye E Ahn, Charles M Farber, Matthew S Davids, et al.
Blood Advances|June 23, 2026
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L Crombie, Inhye E Ahn, Yue Ren, et al.
Ejhaem|July 18, 2022
Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect<sup>®</sup> CLL RegistryJeff P Sharman, Kim Cocks, Chadi Nabhan, et al.
Blood Cancer Journal|February 2, 2023
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitorsDeepti Gadi, Stephen P Martindale, Pui Yan Chiu, et al.
British Journal of Haematology|January 6, 2016
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphomaPhilippe Armand, Robert Redd, Jad Bsat, et al.
Haematologica|July 3, 2025
Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trialGeoffrey Shouse, Canping Chen, Alexandra Muir, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2018
Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL RegistryAnthony Mato, Chadi Nabhan, Neil E Kay, et al.
Pageof 23